Oral recombinant salmon calcitonin tablets are more effective at improving lumbar spine bone mineral density (BMD) after 48 weeks than placebo or a nasal formulation of the hormone, according to the results of a phase 3 multinational double-blind trial. In the study, presented at the American Society for Bone and Mineral Research 2011 Annual Meeting, researchers compared the tablet form of salmon calcitonin with a nasal formulation and placebo in 565 postmenopausal women, 45 years or older, from 6 countries.
At baseline and at weeks 24 and 48, replicate dual-emission X-ray absorptiometry scans showed the oral formulation to be better than the nasal formulation at increasing BMD. In the oral group, lumbar spine BMD increased. In the nasal group, the increase was smaller, and in the placebo group the increase was not significant. At the exit visit, fasting carboxy-terminal collagen crosslink (CTx) serum levels, indicating bone resorption, decreased by 29.9%, 11.4%, and 11.8% in the oral, nasal, and placebo groups, respectively. Most adverse events were mild or moderate in severity.
The formulation is a combination of an organic acid and peptide, which are simultaneously released. It is designed with a coating that prevents opening in the acidic environment of the stomach, but subsequently dissolves in the neutral upper bowel. "It is encouraging to see new forms of osteoporosis treatment options becoming available for clinical use. I will be very interested in further research trials on oral salmon calcitonin," stated the Conference's chairman.
Related Blog Posts
The views expressed in these blog posts are those of the author and not of the Sun-Times News Group.
The views expressed in these blog posts are those of the author and not of the Sun-Times News Group.